APRILBIO

SAFA PLATFORM

SAFAbody™

What’s so good about it?

SAFA-PATENT REGISTERED

-: WO/2015/030539 “AN ANTI SERUM ALBUMIN FAB-EFFECTOR MOIETY FUSION CONSTRUCT, AND THE PREPARING METHOD THEREOF”, published in 2015

-: The patent was registered in Republic of Korea (10-1576561), USA (US9879077), China (105899532), EU (3039038), Japan (2016-538860), Canada (2922618), Colombia (33196), Russia (P-787/3RU), Ukraine (8591/3A/18), Philippine (1/2016/500403), India (201617007424 ), and etc.

Extending the plasma half-life of recombinant biological drugs

What is SAFA?

anti-Serum Albumin Fab-Associated

STEP 01

High affinity anti-SA Fab from HuDVFab library (SL335)
STEP 02

Determination of therapeutic effector proteins (Ab fragments, cytokines or hormones)
STEP 03

Production of fusion proteins by using gene cloning and protein expression system
STEP 04

In vivo administration of a fusion protein binding of fusion protein to SA in the body
STEP 05

Prolonged serum half-life of a SAFA fusion protein drug

STEP 01

High affinity anti-SA Fab from HuDVFab library (SL335)
STEP 02

Determination of therapeutic effector proteins (Ab fragments, cytokines or hormones)
STEP 03

Production of fusion proteins by using gene cloning and protein expression system
STEP 04

In vivo administration of a fusion protein binding of fusion protein to SA in the body
STEP 05

Prolonged serum half-life of a SAFA fusion protein drug

Long serum half life (~19 days) via FcRn recycling mechanism

Diverse & unique pipelines can be developed by

Unique features